Sequencing

Sequencing

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Founded in 2014, Sequencing.com operates at the intersection of consumer genetics, digital health, and personalized medicine. Its business model centers on selling at-home WGS kits, offering one-time comprehensive health reports, and generating recurring revenue through an optional subscription service for monthly report updates. The company differentiates itself through its commitment to full-genome sequencing (30x coverage), robust data privacy, and a platform that allows users to upload existing DNA data from other services. While it serves the wellness and ancestry markets, its primary focus is on actionable health insights for disease risk, pharmacogenomics, rare conditions, and family planning.

Genetics & GenomicsDiagnostics

Technology Platform

Whole Genome Sequencing (30x coverage) platform with continuous bioinformatic reanalysis and a privacy-focused data management system for generating personalized health reports.

Opportunities

Capitalizing on the growing demand for premium, privacy-focused health data by upselling consumers from limited SNP-based tests to full genome sequencing.
The subscription model offers a recurring revenue stream from a single test, leveraging continuous scientific advances to provide ongoing value.

Risk Factors

Intense competition from established, well-funded D2C genetics companies and the challenge of convincing consumers of the superior value of more expensive whole genome sequencing.
Regulatory scrutiny over health-related genetic claims and the significant liability associated with storing highly sensitive biometric data.

Competitive Landscape

Operates in the competitive D2C genetic testing market, competing against giants like 23andMe and AncestryDNA which use cheaper SNP chips. Differentiates through clinical-grade Whole Genome Sequencing, a strong privacy guarantee, and a subscription-based continuous analysis model, targeting a premium, health-focused consumer segment.